IL-21 is an antitolerogenic cytokine of the late-phase alloimmune response

Diabetes

Volumn 60, Issue 12, 2011, Pages 3223-3234

  Petrelli, Alessandra ^a,b   Carvello, Michele ^b,c   Vergani, Andrea ^a,b   Lee, Kang Mi ^c   Tezza, Sara ^a   Du, Ming ^d   Kleffel, Sonja ^a   Chengwen, Liu ^e   Mfarrej, Bechara G ^a   Hwu, Patrick ^e   Secchi, Antonio ^b   Leonard, Warren J ^f   Young, Deborah ^g   Sayegh, Mohamed H ^a   Markmann, James F ^c   Zajac, Allan J ^d   Fiorina, Paolo ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d University of Alabama at Birmingham   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^g PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CD3 ANTIGEN; DOXYCYCLINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 21 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 6; RECOMBINANT CYTOKINE; RECOMBINANT INTERLEUKIN 21; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ALLOIMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CD3+ T LYMPHOCYTE; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; GRAFT SURVIVAL; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANIMALS; ANTIBODIES; ANTIGENS, CD28; ANTIGENS, CD3; APOPTOSIS; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; FORKHEAD TRANSCRIPTION FACTORS; INTERLEUKINS; MICE; MICE, TRANSGENIC; RECEPTORS, INTERLEUKIN-21; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY;

EID: 82255164628     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db11-0880     Document Type: Article

References (40)

1. Walsh PT, Strom TB, Turka LA. Routes to transplant tolerance versus rejection; the role of cytokines. Immunity 2004;20:121-131 (Pubitemid 38258389)
2. Valujskikh A, Baldwin WM 3rd, Fairchild RL. Recent progress and new perspectives in studying T cell responses to allografts. Am J Transplant 2010;10:1117-1125
3. Demirci G, Gao W, Zheng XX, Malek TR, Strom TB, Li XC. On CD28/CD40 ligand costimulation, common gamma-chain signals, and the alloimmune response. J Immunol 2002;168:4382-4390 (Pubitemid 34441338)
4. Coquet JM, Kyparissoudis K, Pellicci DG, et al. IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production. J Immunol 2007;178:2827-2834 (Pubitemid 46333160)
5. Parrish-Novak J, Dillon SR, Nelson A, et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 2000;408:57-63
6. Casey KA, Mescher MF. IL-21 promotes differentiation of naive CD8 T cells to a unique effector phenotype. J Immunol 2007;178:7640-7648 (Pubitemid 46898034)
7. Zhou L, Ivanov II, Spolski R, et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 2007;8:967-974 (Pubitemid 47300011)
8. Korn T, Bettelli E, Gao W, et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2007;448:484-487 (Pubitemid 47123515)
9. Nurieva R, Yang XO, Martinez G, et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 2007;448:480-483 (Pubitemid 47123514)
10. Bucher C, Koch L, Vogtenhuber C, et al. IL-21 blockade reduces graftversus- host disease mortality by supporting inducible T regulatory cell generation. Blood 2009;114:5375-5384
11. Hanash AM, Kappel LW, Yim NL, et al. Abrogation of donor T cell IL-21 signaling leads to tissue-specific modulation of immunity and separation of GVHD from GVL. Blood 2011;118:446-455
12. Peluso I, Fantini MC, Fina D, et al. IL-21 counteracts the regulatory T cellmediated suppression of human CD4+ T lymphocytes. J Immunol 2007; 178:732-739 (Pubitemid 46095145)
13. McGuire HM, Walters S, Vogelzang A, et al. Interleukin-21 is critically required in autoimmune and allogeneic responses to islet tissue in murine models. Diabetes 2011;60:867-875
14. Li Y, Yee C. IL-21 mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes. Blood 2008;111:229-235
15. Spolski R, Kim HP, Zhu W, Levy DE, Leonard WJ. IL-21 mediates suppressive effects via its induction of IL-10. J Immunol 2009;182:2859-2867
16. Zheng Q, Xu Y, Liu Y, et al. Induction of Foxp3 demethylation increases regulatory CD4+CD25+ T cells and prevents the occurrence of diabetes in mice. J Mol Med (Berl) 2009;87:1191-1205
17. Zheng Y, Josefowicz SZ, Kas A, Chu TT, Gavin MA, Rudensky AY. Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature 2007;445:936-940
18. Baan CC, Balk AH, Dijke IE, et al. Interleukin-21: an interleukin-2 dependent player in rejection processes. Transplantation 2007;83:1485-1492 (Pubitemid 46934072)
19. Vergani A, D'Addio F, Jurewicz M, et al. A novel clinically relevant strategy to abrogate autoimmunity and regulate alloimmunity in NOD mice. Diabetes 2010;59:2253-2264
20. Fantini MC, Dominitzki S, Rizzo A, Neurath MF, Becker C. In vitro generation of CD4+ CD25+ regulatory cells from murine naive T cells. Nat Protoc 2007;2:1789-1794
21. Venken K, Thewissen M, Hellings N, et al. A CFSE based assay for measuring CD4+CD25+ regulatory T cell mediated suppression of autoantigen specific and polyclonal T cell responses. J Immunol Methods 2007;322:1-11 (Pubitemid 46560587)
22. Young DA, Hegen M, Ma HL, et al. Blockade of the interleukin-21/ interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis. Arthritis Rheum 2007;56:1152-1163 (Pubitemid 46608640)
23. Jin H, Carrio R, Yu A, Malek TR. Distinct activation signals determine whether IL-21 induces B cell costimulation, growth arrest, or Bim-dependent apoptosis. J Immunol 2004;173:657-665 (Pubitemid 38797396)
24. Cejas PJ, Walsh MC, Pearce EL, et al. TRAF6 inhibits Th17 differentiation and TGF-beta-mediated suppression of IL-2. Blood 2010;115:4750-4757
25. Vincenti F, Larsen C, Durrbach A, et al.; Belatacept Study Group. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005;353:770-781 (Pubitemid 41215486)
26. Cobbold SP, Adams E, Graca L, et al. Immune privilege induced by regulatory T cells in transplantation tolerance. Immunol Rev 2006;213:239-255 (Pubitemid 44401505)
27. Le Moine A, Goldman M. Non-classical pathways of cell-mediated allograft rejection: new challenges for tolerance induction? Am J Transplant 2003;3: 101-106 (Pubitemid 36323107)
28. Brady J, Hayakawa Y, Smyth MJ, Nutt SL. IL-21 induces the functional maturation of murine NK cells. J Immunol 2004;172:2048-2058 (Pubitemid 38182350)
29. Choi J, Ritchey J, Prior JL, et al. In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versusleukemia. Blood 2010;116:129-139
30. Monti P, Scirpoli M, Maffi P, et al. Islet transplantation in patients with autoimmune diabetes induces homeostatic cytokines that expand autoreactive memory T cells. J Clin Invest 2008;118:1806-1814 (Pubitemid 351632383)
31. Britsch S, Goerich DE, Riethmacher D, et al. The transcription factor Sox10 is a key regulator of peripheral glial development. Genes Dev 2001;15:66-78 (Pubitemid 32060683)
32. Gopalkrishnan RV, Christiansen KA, Goldstein NI, DePinho RA, Fisher PB. Use of the human EF-1alpha promoter for expression can significantly increase success in establishing stable cell lines with consistent expression: a study using the tetracycline-inducible system in human cancer cells. Nucleic Acids Res 1999;27:4775-4782 (Pubitemid 30006668)
33. O'Sullivan BJ, Thomas HE, Pai S, et al. IL-1 beta breaks tolerance through expansion of CD25+ effector T cells. J Immunol 2006;176:7278-7287 (Pubitemid 43849028)
34. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006;441:235-238
35. Huber M, Steinwald V, Guralnik A, et al. IL-27 inhibits the development of regulatory T cells via STAT3. Int Immunol 2008;20:223-234 (Pubitemid 351234390)
36. Davalli AM, Ogawa Y, Ricordi C, Scharp DW, Bonner-Weir S, Weir GC. A selective decrease in the beta cell mass of human islets transplanted into diabetic nude mice. Transplantation 1995;59:817-820
37. Ricordi C, Inverardi L, Kenyon NS, Goss J, Bertuzzi F, Alejandro R. Requirements for success in clinical islet transplantation. Transplantation 2005;79:1298-1300 (Pubitemid 40734788)
38. Kessler L, Parissiadis A, Bayle F, et al.; GRAGIL Study Group. Evidence for humoral rejection of a pancreatic islet graft and rescue with rituximab and IV immunoglobulin therapy. Am J Transplant 2009;9:1961-1966
39. Nankivell BJ, Alexander SI. Rejection of the kidney allograft. N Engl J Med 2010;363:1451-1462
40. Webber A, Hirose R, Vincenti F. Novel strategies in immunosuppression: issues in perspective. Transplantation 2011;91:1057-1064